The ALS Association has awarded Mitochon Pharmaceuticals a $1 million grant to support a Phase 2 clinical trial testing the company’s experimental therapy MP-101 in people with amyotrophic lateral sclerosis (ALS). The study is still in the planning stages and is expected to kick off next year.
News
Higher levels of physical activity were associated with a lower risk of developing amyotrophic lateral sclerosis (ALS) in a large U.K. study. The association was seen using both self-reported activity questionnaires and objective measurements from wrist-worn devices called accelerometers. Among participants with known genetic risk factors for ALS,…
A modified frailty index based on five self-reported health measures may help identify people at higher risk of developing amyotrophic lateral sclerosis (ALS), according to a new study. The model, which included falls, whole-body pain, long-standing illness or disability, self-rated health, and tiredness or lethargy in the previous two…
Stem cell therapies are generally safe and well tolerated in people with amyotrophic lateral sclerosis (ALS), and preliminary evidence from clinical trials suggests they may also help slow functional decline, according to a systematic review and meta-analysis of several published studies. Researchers found that people given stem cell therapies…
Loneliness and regret are key drivers of mental health distress among people with amyotrophic lateral sclerosis (ALS), according to a new survey — but the researchers also found that maintaining a hopeful outlook may help those with the rare disease to combat anxiety, depression, and frustration. The survey,…
Researchers, physicians, industry partners, caregivers, and people with amyotrophic lateral sclerosis (ALS) are gearing up to gather for the third annual ALS Nexus conference, an effort from the ALS Association to bring the ALS community together around a shared goal of changing the future of ALS. The…
People with amyotrophic lateral sclerosis (ALS) who have a history of strenuous exercise tend to develop the disease earlier than patients who were less physically active, according to a study. However, data showed that heavy exercise does not increase the risk of death for ALS patients, and exercise itself…
Analyses of vocal recordings using artificial intelligence (AI) may aid in the diagnosis of amyotrophic lateral sclerosis (ALS), particularly among those with a form of the disease called bulbar-onset ALS that initially affects the mouth and throat, a new study suggests. Bulbar-onset ALS generally has a poorer prognosis than…
New analyses of data from two Phase 2 clinical trials and observational studies suggest that changes in blood levels of neurofilament light chain (NfL), a biomarker of nerve damage, may help predict which people with amyotrophic lateral sclerosis (ALS) are more likely to experience clinical benefits with Clene’s…
Neurosense Therapeutics plans to seek Health Canada approval by the end of the year for PrimeC, its experimental oral therapy for amyotrophic lateral sclerosis (ALS). The planned new drug submission (NDS) filing follows completion of a pre-NDS process and finalization of the related meeting minutes. The process is…
Recent Posts
- Measuring proteins in tears may help in diagnosing ALS, per study
- Small wins matter when living with ALS
- MDA Engage: National ambassador brings message of belonging, resilience
- Specialized ALS care linked to longer survival in real-world study
- New AI model shows promise for spotting genetic ALS risk, study says